|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease:a systematic review and Meta-analysis显示文摘OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) based on high-quality randomized placebocontrolled trials.METHODS:We searched PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,Chinese Biomedical Literature Database,China Science and Technology Journal Database,and Wanfang databases for randomized placebo-controlled trials of CHM treatment for AECOPD from inception to June 4,2021.The Cochrane Collaboration’s tool and the Grading of Recommendations,Assessment,Development and Evaluation were used to assess the risk of bias and the evidence quality of the included studies.Revman 5.3 software was used for Meta-analysis.RESULTS:A total of 9 trials involving 1591 patients were included.The Meta-analysis showed that based on CWM treatment,CHM group had significant advantages over the placebo group in ameliorating clinical total effective rate [RR = 1.29,95% CI(1.07,1.56),P = 0.007,low quality] and TCM symptom scores [MD =-2.99,95% CI(-4.46,-1.53),P < 0.0001,moderate quality],improving arterial blood gas results [PaO_(2):MD = 4.51,95% CI(1.97,7.04),P = 0.0005,moderate quality;PaCO_(2):MD =-2.87,95% CI(-4.28,-1.46),P < 0.0001,moderate quality],reducing CAT scores [MD =-2.08,95% CI(-2.85,-1.31),P < 0.000 01,moderate quality],length of hospitalization [MD =-1.87,95% CI(-3.33,-0.42),P = 0.01,moderate quality],and acute exacerbation rate [RR = 0.60,95% CI(0.43,0.83),P = 0.002,moderate quality].No serious CHM-related adverse events were reported.CONCLUSIONS:The current evidence indicates that CHM is an effective and well-tolerated adjunct therapy for AECOPD patients receiving CWM.However,considering the high heterogeneity,this conclusion requires confirmation. | GUO Wen LI Xuanlin ZHAO Hulei LEI Siyuan XIE Yang LI Jiansheng | 2023 | Journal of Traditional Chinese Medicine2023，43，2： | 1 |
| 2 | A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma显示文摘The RAS/mitogen-activated protein kinase(MAPK)pathway disorder induced by the missense mutations in the tyrosine-protein phosphatase non-receptor type 11(PTPN11)gene which resulted in the nonreceptor protein tyrosine phosphatase SHP2 dysfunction has been reported in many lung cancer cases.Moreover,the Src homology region 2(SH2)-containing protein tyrosine phosphatase 2(SHP2)mutation or deletion triggers multiple signaling pathway dysfunctions including RAS/MAPK,RAS/extracellular-signal-regulated kinase(ERK),phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT),Janus kinase/signal transducers and activators of transcription(JAK/STAT)and Hippo/yes-associated protein(YAP)which affect the expression of growth factors,cytokines and hormones.In recent years,the developing of the small molecule SHP2 inhibitors received a lot of attention.In this review,we summarize the recent years'progresses of the SHP2 inhibitors development for the lung cancer treatment. | Qing Niana Jinhao Zenga Li He Yu Chen Zhiqiang Zhang Fernando Rodrigues-Lima Liyun Zhao Xuanlin Feng Jianyou Shi | 2021 | Chinese Chemical Letters2021，32，5： | 1 |
| 3 | ROCK inhibitor:Focus on recent updates显示文摘Rho-associated coiled-coil-containing protein kinase(RoCK)belongs to the serine-threonine family,and RoCK is involved in a variety of biological processes including cell migration,adhesion,proliferation and differentiation through phosphorylation of different downstream substrates.The aberrant activation of ROCK is associated with the pathological conditions in different systems including various diseases,including cancer,neurological diseases,inflammation,cardiovascular diseases and glaucoma.Therefore,the ROCK inhibitors have potential applicability for treating the aforementioned diseases.Four small molecule ROCK inhibitors have been approved for clinical use:fasudil,ripasudil,netarsudil and belumosudil.In recent years,more small molecule ROCK inhibitors have been identified.This paper reviews the ROCK inhibitors reported in past seven years.We mainly focused on the summarization of the structure-activity relationships,inhibitory efficacy,pharmacological mechanisms and the relevant clinical studies of the reported ROCK inhibitors.Besides the small molecular inhibitors,the peptides and biological extracts which exhibit ROCK inhibitory effects are also included.We also provide suggestions for the future development of the potent ROCK inhibitors. | Yaodong You Kun Zhu Jie Wang Qi Liang Wen Li Lin Wang Baojun Guo Jing Zhou Xuanlin Feng Jianyou Shi | 2023 | Chinese Chemical Letters2023，34，12： | 0 |
| 4 | Flash Flood Disaster Assessment in Yuzhou District显示文摘Based on the basic maps,attribute data of watershed and outcomes of flash flood disaster investigation,this paper presents the techniques and achievements for flash flood disaster assessment in Yuzhou district. The primary preparedness for assessment was firstly introduced.Then,it was demonstrated that the main works of assessment,including design flood by rainfall-runoff modeling in watersheds,existing flood control capacity estimation,critical rainfall and stages determination,and flood dangerous zoning for the riverside villages in mountain-hill-area in Yuzhou district. Finally,some suggestions were provided to support flash flood management in Yuzhou district,including mining information from outcomes of flash flood disaster investigation and assessment,improving the monitoring and early warning system on flash flood,and identifying potential flash flood types and areas. | Li Changzhi Zhang Miao Zhang Qiyi Weng Jiachao Huang Xuanlin | 2017 | Meteorological and Environmental Research2017，8，3： | 0 |
| 5 | Recent research and development of DYRK1A inhibitors显示文摘Dual specificity tyrosine phosphorylation regulated kinase 1 A(DYRK1 A) is an evolutionarily conserved protein kinase belonging to the CMGC kinase family, which is closely related to Down syndrome(DS)and Alzheimer’s disease(AD). In recent years, not only the treatment of diabetes, but also the treatment of cancer gradually focuses on targeting DYRK1 A. Therefore, a series of DYRK1 A inhibitors have been developed to treat relevant diseases and clarify their treatment mechanism furtherly. DYRK1 A inhibitors are mainly divided into natural products and synthetic compounds. Among them, harmine is an excellent DYRK1 A inhibitor. Therefore, the synthetic DYRK1 A inhibitors are mainly based on harmine, which greatly enriches the structure and quantity of DYRK1 A inhibitors. The interaction between the inhibitors and the DYRK1 A protein has a guiding significance in predicting the activity of the inhibitors, and plays an irreplaceable role in the design of the compounds. This paper mainly reviews DYRK1 A inhibitors found in recent years and their structure-activity relationship, looking forward to providing a theoretical basis for the development of DYRK1 A inhibitors. | Liyun Zhao Xuan Xiong Li Liu Qi Liang Rongsheng Tong Xuanlin Feng Lan Bai Jianyou Shi | 2022 | Chinese Chemical Letters2022，33，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员